SecBot SecBot
6-K ·Filed Nov 12, 2026

GMAB

GENMAB A/S
NEUTRAL
Impact 2/10
Horizonimmediate Processed4d 9h ago SEC0001434265-26-000157
Notable filing: 6-K
Actionable Insight • Neutral

These are routine insider sales by non-executive board members, not a signal of deteriorating fundamentals. Monitor upcoming quarterly results for any changes in revenue or pipeline progress.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$51.74
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.72%
T+1 · $51.37
Vs SPY
−0.35%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $51.74entry
  2. T+1 · 4d ago −0.72%α −0.35% · $51.37
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Genmab filed a Form 6-K disclosing routine insider share sales by two board members. Board member Martin Schultz sold 617 shares at DKK 3,540.87 and board member Mijke Zachariasse sold 351 shares at the same price, both on November 12, 2026. The filing contains no financial results, guidance, or material corporate events.

Key Facts

  • Board member Martin Schultz sold 617 shares at DKK 3,540.87 per share on Nov 12, 2026
  • Board member Mijke Zachariasse sold 351 shares at DKK 3,540.87 per share on Nov 12, 2026
  • Total proceeds from both sales approximately DKK 3.43 million (about $485,000 at current rates)
  • The sales represent a tiny fraction of the company's $33.7B market cap
  • No periodic financial results, guidance, or other material information was included in the filing

Financial Impact

Insider sales of approximately DKK 3.43 million total, immaterial relative to $33.7B market cap

Risk Factors

  • No financial data or guidance provided in this filing
  • Insider sales are small and routine, no material risk signal

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000157
Document: gmab_20261112x6kx4.htm0001434265-26-000157
Document: 0001434265-26-000157-index-headers.html0001434265-26-000157
Document: 0001434265-26-000157-index.html0001434265-26-000157
Document: 0001434265-26-000157.txt0001434265-26-000157
Earnings Context (Synthetic; results releases only)0001434265-26-000157

Track record

31 reports on GMAB

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Viewing Entry $51.74 Now $51.57 −0.33% settles Dec 11
  3. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
  4. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
  5. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
  6. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
  7. Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 Now $51.57 −4.62% settles Dec 9
  8. Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
  9. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
  10. Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
Showing 10 of 31

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026